Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 3;105(7):1937–1947. doi: 10.3324/haematol.2019.226407

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Post-hoc analysis according to frailty status in patients treated with different maintenance treatments. (A, B) Progression-free survival (PFS) (A) and overall survival (OS) (B) in fit patients according to treatment arm. (C, D) PFS (C) and OS (D) in intermediate-fit patients according to treatment arm. (E, F) PFS (E) and OS (F) in frail patients according to treatment arm. All time to events were calculated from the time of random assignment to maintenance treatment arms (_m). R: lenalidomide; RP: lenalidomide-prednisone; PFS_m: progression-free survival from the random assignment to maintenance treatment arms; OS_m: overall survival from the random assignment to maintenance treatment arms; HR: hazard ratio; CI: confidence interval; P: P value.